You are here

  • Home
  • Archive
  • Volume 11, Issue 12
  • Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer

 

Online download statistics by month:

Online download statistics by month: December 2023 to July 2025

AbstractFullPdf
Dec 2023460464142
Jan 2024171173122
Feb 2024989859
Mar 2024929273
Apr 2024909049
May 2024707044
Jun 2024767642
Jul 2024939356
Aug 2024787832
Sep 2024516436
Oct 2024686828
Nov 2024919260
Dec 2024697045
Jan 2025555528
Feb 2025696937
Mar 2025828253
Apr 2025939347
May 2025575841
Jun 2025484832
Jul 2025220
Total191319351026